Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.